title: Effectiveness and gastrointestinal tolerability during conversion and titration with once-daily OROS® hydromorphone extended release in opioid-tolerant patients with chronic low back pain.
abstract: OBJECTIVE
  To describe the efficacy and safety of hydromorphone extended-release tablets (OROS hydromorphone ER) during dose conversion and titration.
  
  
  METHODS
  A total of 459 opioid-tolerant adults with chronic moderate to severe low back pain participated in an open-label, 2- to 4-week conversion/titration phase of a double-blind, placebo-controlled, randomized withdrawal trial, conducted at 70 centers in the United States. Patients were converted to once-daily OROS hydromorphone ER at 75% of the equianalgesic dose of their prior total daily opioid dose (5:1 conversion ratio), and titrated as frequently as every 3 days to a maximum dose of 64 mg/day. The primary outcome measure was change in pain intensity numeric rating scale; additional assessments included the Patient Global Assessment and the Roland-Morris Disability Questionnaire scores. Safety assessments were performed at each visit and consisted of recording and monitoring all adverse events (AEs) and serious AEs.
  
  
  RESULTS
  Mean (standard deviation) final daily dose of OROS hydromorphone ER was 37.5 (17.8) mg. Mean (standard error of the mean [SEM]) numeric rating scale scores decreased from 6.6 (0.1) at screening to 4.3 (0.1) at the final titration visit (mean [SEM] change, -2.3 [0.1], representing a 34.8% reduction). Mean (SEM) change in Patient Global Assessment was -0.6 (0.1), and mean change (SEM) in the Roland-Morris Disability Questionnaire was -2.8 (0.3). Patients achieving a stable dose showed greater improvement than patients who discontinued during titration for each of these measures (P < 0.001). Almost 80% of patients achieving a stable dose (213/268) had a ≥30% reduction in pain. Commonly reported AEs were constipation (15.4%), nausea (11.9%), somnolence (8.7%), headache (7.8%), and vomiting (6.5%); 13.0% discontinued from the study due to AEs.
  
  
  CONCLUSIONS
  The majority of opioid-tolerant patients with chronic low back pain were successfully converted to effective doses of OROS hydromorphone ER within 2 to 4 weeks.
authors: Gold Coast Research, LLC, Weston, FL, USA.
authors: Martin E
authors: ME
authors: Hale
authors: Srinivas R
authors: SR
authors: Nalamachu
authors: Arif
authors: A
authors: Khan
authors: Michael
authors: M
authors: Kutch
keywords: OROS hydromorphone ER; chronic low back pain; conversion and titration; extended-release opioids; noncancer pain; opioid rotation
references: Anesthesiology. 2002 Oct;97(4):827-36
references: 12357147
references: J Pain Symptom Manage. 2003 Feb;25(2):169-78
references: 12590032
references: J Pain Symptom Manage. 2009 Sep;38(3):418-25
references: 19735902
references: Pain Pract. 2011 May-Jun;11(3):282-9
references: 20854307
references: J Pain. 2009 Feb;10(2):113-30
references: 19187889
references: J Clin Oncol. 1996 May;14(5):1713-7
references: 8622092
references: Postgrad Med. 2011 Mar;123(2):119-30
references: 21474900
references: South Med J. 2000 Oct;93(10):946-52; quiz 953
references: 11147475
references: Pain Med. 2009 Jul;10 Suppl 2:S79-88
references: 19691687
references: Int J Clin Pract. 2007 Oct;61(10):1671-6
references: 17877652
references: CMAJ. 2006 May 23;174(11):1589-94
references: 16717269
references: Am J Ther. 2008 Jul-Aug;15(4):312-20
references: 18645331
references: J Am Geriatr Soc. 2010 Jul;58(7):1353-69
references: 20533971
references: J Opioid Manag. 2010 Sep-Oct;6(5):351-8
references: 21046932
references: Cancer. 1996 Aug 15;78(4):852-7
references: 8756381
references: J Int Med Res. 2008 Mar-Apr;36(2):343-52
references: 18380946
references: J Psychoactive Drugs. 2003 Apr-Jun;35(2):253-9
references: 12924748
references: J Pain Symptom Manage. 2005 May;29(5 Suppl):S57-66
references: 15907647
references: Anesthesiology. 1975 May;42(5):602-7
references: 48347
references: Pain Pract. 2010 Sep-Oct;10(5):404-15
references: 20384968
references: BMC Palliat Care. 2009 Sep 15;8:14
references: 19754935
references: Curr Med Res Opin. 2009 Sep;25(9):2133-50
references: 19601703
references: Expert Opin Drug Deliv. 2010 Jan;7(1):137-44
references: 19961358
references: J Pain Symptom Manage. 2002 May;23(5):355-68
references: 12007754
references: Pain Med. 2010 Oct;11(10):1477-88
references: 21199302
references: BMC Palliat Care. 2008 Oct 31;7:17
references: 18976472
references: Pain. 1992 Apr;49(1):87-91
references: 1375728
references: Cancer. 1994 Sep 15;74(6):1808-16
references: 7521784
references: Pain Pract. 2009 Nov-Dec;9(6):468-79
references: 19874536
references: Expert Opin Pharmacother. 2011 Aug;12(11):1757-68
references: 21609187
references: J Pain Symptom Manage. 2009 Sep;38(3):426-39
references: 19735903
references: J Pain Symptom Manage. 2003 May;25(5):406-11
references: 12727037
references: Pain. 2008 Sep 15;138(3):507-513
references: 18342447
references: Anesth Analg. 2000 Apr;90(4):933-7
references: 10735802
references: Ann Intern Med. 2007 Oct 2;147(7):505-14
references: 17909211
references: Cancer. 1999 Nov 1;86(9):1856-66
references: 10547561
references: Curr Med Res Opin. 2010 Jun;26(6):1505-18
references: 20429852
references: Curr Med Res Opin. 2009 May;25(5):1045-55
references: 19292602
references: Pain. 2001 Nov;94(2):149-158
references: 11690728
references: Am J Drug Alcohol Abuse. 1987;13(3):293-308
references: 3687892
references: Pain. 2004 Dec;112(3):372-380
references: 15561393
references: Expert Opin Pharmacother. 2004 Feb;5(2):469-72
references: 14996642
references: Clin Pharmacol Ther. 2003 Aug;74(2):102-12
references: 12891220
references: Am J Med. 2009 Oct;122(10 Suppl):S13-21
references: 19801048
references: Curr Med Res Opin. 2007 May;23(5):981-9
references: 17519065